Science 37 has secured a $6.5 million Series A financing round co-led by Lux Capital and dRx Capital, a joint venture between Qualcomm and Novartis. The funds will be used to the development and rollout of the company’s new operating model, which solves some of the greatest inefficiencies in conducting clinical trials.

“Accelerating clinical trials is possible – but only if we make it easier for people to participate,” said Noah Craft, MD, PhD, and co-founder and CEO of Science 37. “Clinical research design and delivery is one of the few industries that has yet to be disrupted by technology – Science 37 uses mobile engagement and locally delivered medical services to bring clinical trials to scale.”

Science 37’s new metasite operating model promises to deliver end-to-end clinical trial services under a single contract by leveraging partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups and other technology companies to maximize efficiency. The company is built on design-thinking principles and rapid prototyping to bring clinical trials to patients at home and in local care circles.

Science 37’s platform, the Network Oriented Research Assistant (NORA), utilizes telemedicine and coordinates mobile workforces to overcome geographic barriers and unlock access, so anyone can take part in trials, including underserved and minority populations. NORA makes sure participants are better engaged with researchers and their staff, allowing for better collection of high-quality real world data, improved medication adherence and safety monitoring, and an increased likelihood of trial success.

Science 37 is already proving its effectiveness by creating the only technology-enabled metasite in a Phase III FDA-registered trial with a major pharmaceutical company. In this rare disease trial, the company is directly recruiting participants from approximately 25 percent of the U.S. population and is far exceeding expectations on performance, while ensuring high patient satisfaction.